VALNEVA revenue breakdown overview

VALNEVA revenue for the last year amounted to 153.70 M EUR, the most of which — 153.71 M EUR — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines. The greatest contribution to the revenue figure was made by United States — last year it brought VALNEVA 32.96 M EUR, and the year before that — -23.80 M EUR.